The trial examined the efficacy of Apollo Endosurgery’s ORBERA Intragastric Balloon as a weight loss treatment. The trial included 125 patients in the randomized treatment group and 130 patients in the randomized control group. The ORBERA group lost twice as much weight as the control group at six months.
“At the completion of the study, it was clear that the ORBERA Intragastric Balloon produced significant weight loss and quality of life benefits, when compared to the study’s control group,” said Barham Abu Dayyeh, MD, a gastroenterologist with Mayo Clinic in Rochester, Minn.
More articles on gastroenterology:
Making the switch to employment in gastroenterology: Key words of advice
GI physician leader to know: Dr. Steven Morris of Atlanta Gastroenterology Associates
14 GI physicians making headlines – May 15, 2015
